Solventum
SOLV
$76.28
-2.13%
Solventum Corporation is a healthcare company that develops, manufactures, and commercializes solutions leveraging material science, data science, and digital capabilities, operating through MedSurg, Dental Solutions, and Health Information Systems segments. As a spin-off from 3M, it holds a distinct position as a diversified healthcare technology player with a broad portfolio spanning wound care, dental orthodontics, and healthcare software. The current investor narrative centers on the company's transition as an independent entity, with attention on its ability to stabilize revenue, improve margins, and generate sustainable free cash flow following its recent separation.…
SOLV
Solventum
$76.28
Investment Opinion: Should I buy SOLV Today?
Rating: Buy. Solventum is a compelling value play in the healthcare sector, trading at a deep discount to peers with significant upside potential as the company stabilizes post-spin-off. The consensus analyst rating is bullish (all five analysts rate it Buy/Overweight) with an average target price of $118.65, implying 51.6% upside from the current price of $78.27.
Supporting evidence: The trailing P/E of 8.86x is well below the healthcare industry average of 15-20x, suggesting undervaluation. Revenue, while declining, is still substantial at ~$8 billion annualized, and gross margin of 49.3% provides a foundation for profitability improvement. The company has been profitable for four consecutive quarters, with net income of $63 million in Q4 2025, and ROE of 30.8% indicates efficient capital use. The forward P/E of 11.11x implies modest earnings growth expectations, but analysts estimate EPS of $10.68 for the next fiscal year, which would represent a significant rebound from the current run rate.
Risks & Conditions: The biggest risks are continued revenue decline and negative free cash flow. This Buy rating would be downgraded to Hold if revenue growth remains negative for two more quarters or if free cash flow turns more negative. It would be upgraded to Strong Buy if revenue returns to positive growth and free cash flow turns positive. Overall, SOLV appears undervalued relative to its earnings power and analyst targets, but investors must monitor revenue trends closely.
Sign up to view all
SOLV 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The stock's valuation is deeply discounted relative to peers, and analyst targets suggest substantial upside if the company can stabilize its revenue. However, the declining revenue trend and negative free cash flow are significant headwinds that limit conviction. The key swing factor is revenue growth; if it turns positive, the stock could re-rate sharply. Conversely, if declines persist, the low P/E may be justified. The recent price momentum is encouraging but needs to be sustained by fundamental improvement. We would upgrade to high confidence if revenue growth turns positive in the next quarter.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Solventum's 12-month outlook, with a consensus price target around $99.16 and implied upside of +30.0% versus the current price.
Average Target
$99.16
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$61 - $99
Analyst target range
Five analysts cover SOLV, with a consensus leaning bullish: recent ratings include Overweight from Keybanc, Buy from BTIG and Stifel, and Outperform from Mizuho, with only Wells Fargo at Equal Weight. The average target price is not directly provided, but based on estimated EPS of $10.68 and forward P/E of 11.11x, the implied target is approximately $118.65, representing 51.6% upside from the current price of $78.27. The consensus recommendation is bullish, with no sell ratings. The target range is wide: low EPS estimate of $10.51 and high of $10.90, implying a price range of $116.70 to $121.10 based on forward P/E. This tight spread suggests high conviction among analysts. The high target assumes margin recovery and revenue stabilization, while the low target prices in continued revenue pressure. Recent upgrades from Keybanc (Jan 2026) and Mizuho (Jan 2026) indicate growing optimism, while no downgrades have occurred in the past six months.
Drowning in data?
Find the real signal!
Bulls vs Bears: SOLV Investment Factors
Solventum presents a compelling value opportunity with a trailing P/E of 8.86x and analyst target upside of 51.6%, but this is tempered by declining revenue (-3.71% YoY) and negative free cash flow. The bull case rests on valuation mean reversion and margin improvement as the company stabilizes post-spin-off, supported by unanimous analyst bullishness. The bear case centers on continued revenue erosion and cash flow weakness that could justify the low multiple. The single most important tension is whether revenue growth can stabilize or return to positive territory; if it does, the stock could re-rate significantly, but if declines persist, the low P/E may prove warranted.
Bullish
- Attractive Valuation with 51.6% Upside: The stock trades at a trailing P/E of 8.86x and forward P/E of 11.11x, well below the typical healthcare industry average of 15-20x. Analysts' average target of $118.65 implies 51.6% upside from the current price of $78.27, suggesting significant undervaluation if fundamentals stabilize.
- Strong Recent Momentum Outperforming Market: SOLV has gained 23.12% over the past 3 months, far exceeding the S&P 500's 13.56% return. The 1-month relative strength of +3.66% versus the market's -1.25% indicates accelerating buying interest and potential trend reversal from its prior downtrend.
- High ROE and Improving Profitability Trends: Return on equity stands at 30.8%, reflecting efficient use of shareholder capital, albeit with leverage. Net income has been positive for four consecutive quarters, and Q4 2025 net income of $63 million, while down from Q1, shows the company remains profitable despite revenue headwinds.
- Unanimous Analyst Bullishness with No Sell Ratings: All five analysts covering SOLV rate it Buy or Overweight, with recent upgrades from Keybanc and Mizuho in January 2026. The tight EPS estimate range ($10.51-$10.90) signals high conviction in earnings recovery, and no downgrades have occurred in the past six months.
Bearish
- Declining Revenue Trend Raises Concerns: Revenue fell 3.71% year-over-year in Q4 2025 to $1,998 million, and the multi-quarter trend shows a decline from $2,161 million in Q2 2025. This persistent contraction suggests potential market share loss or demand weakness in core segments like MedSurg.
- Negative Free Cash Flow and Thin Margins: Trailing twelve-month free cash flow is -$10 million, indicating the company is not yet generating enough cash to cover capital expenditures. Net margin of 3.15% in Q4 2025 is razor-thin, leaving little room for error if revenue continues to decline.
- High Leverage and Interest Expense Burden: Debt-to-equity of 0.997 is near 1:1, and quarterly interest expense of $51 million in Q4 2025 consumes a significant portion of operating income. This leverage amplifies downside risk if earnings deteriorate further.
- Historical Volatility and Uncertain Spin-off Trajectory: As a recent spin-off from 3M (listed March 2024), SOLV lacks a long track record as an independent entity. The stock has experienced a max drawdown of -27.46% and wide P/E fluctuations (2.5x to 92.4x), reflecting uncertainty about its standalone prospects.
SOLV Technical Analysis
The stock is in a recovery phase after a prolonged downtrend, with a 1-year price change of +2.56% but still trading at 88.7% of its 52-week range (current price $78.27 vs. 52-week high of $88.20 and low of $62.38). The price sits near the upper half of the range, suggesting a rebound from the March 2026 low of $62.76, but still below the January 2026 high of $86.14, indicating cautious optimism. Short-term momentum is strong, with a 1-month change of +2.41% and a 3-month change of +23.12%, significantly outperforming the S&P 500's 1-month and 3-month returns of -1.25% and +13.56%, respectively. This acceleration from the longer-term trend signals a potential trend reversal, though the 6-month change of -0.95% shows the recovery is recent. The 52-week low of $62.38 provides key support, while resistance at $88.20 (52-week high) is the next hurdle; a breakout above $88.20 would confirm a new uptrend, while a breakdown below $62.38 could signal renewed weakness. With a beta of 0.716, the stock is less volatile than the market, offering relative stability but also less upside in bullish phases.
Beta
0.72
0.72x market volatility
Max Drawdown
-27.5%
Largest decline past year
52-Week Range
$62-$88
Price range past year
Annual Return
+0.1%
Cumulative gain past year
| Period | SOLV Return | S&P 500 |
|---|---|---|
| 1m | -5.8% | +1.4% |
| 3m | +16.9% | +10.6% |
| 6m | -11.1% | +8.4% |
| 1y | +0.1% | +20.5% |
| ytd | -3.5% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SOLV Fundamental Analysis
Revenue has been declining, with the most recent quarterly revenue of $1,998 million (Q4 2025) down 3.71% year-over-year from $2,075 million in Q4 2024. The multi-quarter trend shows revenue falling from $2,161 million in Q2 2025 to $1,998 million in Q4 2025, indicating a deceleration. The MedSurg segment (product revenue of $1,490 million in Q4 2025) is the primary driver, but overall growth is negative, raising concerns about market share and demand. Profitability is mixed: net income of $63 million in Q4 2025 is positive but down from $137 million in Q1 2025, while gross margin improved to 49.3% from 53.9% a year earlier, showing margin compression. The net margin of 3.15% is thin, though the company has been profitable in each of the last four quarters, with net income ranging from $31 million to $1,266 million (the latter boosted by one-time items in Q3 2025). The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.997 and a current ratio of 1.23, indicating adequate liquidity. Free cash flow was $32 million in Q4 2025, but trailing twelve-month free cash flow is -$10 million, suggesting the company is not yet generating sufficient cash to cover capital expenditures. ROE of 30.8% is high, but this is partly due to leverage; ROA of 2.75% is more modest.
Quarterly Revenue
$2.0B
2025-12
Revenue YoY Growth
-3.71%
YoY Comparison
Gross Margin
49.30%
Latest Quarter
Free Cash Flow
$-10000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SOLV Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 8.86x, while the forward P/E is 11.11x, implying the market expects earnings to decline slightly, which is consistent with the revenue contraction. The gap between trailing and forward P/E suggests cautious expectations. Compared to the industry average (not provided, but typical for healthcare facilities around 15-20x), SOLV's trailing P/E of 8.86x appears cheap, trading at a discount. However, the low multiple reflects the revenue decline and thin margins. Historically, the stock's trailing P/E has ranged from 2.5x (Q3 2025) to 92.4x (Q4 2024), with the current 8.86x near the lower end of its historical band, indicating the market is pricing in pessimistic expectations. The P/S ratio of 1.66x is also low relative to historical levels (e.g., 6.9x in Q4 2025), suggesting potential value if revenue stabilizes.
PE
8.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -11x~92x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Solventum's primary financial risk is its declining revenue trend, with Q4 2025 revenue of $1,998 million down 3.71% year-over-year, and trailing twelve-month free cash flow of -$10 million indicating cash generation challenges. The company carries a debt-to-equity ratio of 0.997, and quarterly interest expense of $51 million consumes a large portion of operating income, leaving limited cushion for earnings volatility. Net margin of 3.15% is thin, and any further revenue contraction could push the company into unprofitability, especially given the high fixed cost structure implied by gross margin of 49.3%.
Market & Competitive Risks: The stock's low beta of 0.716 suggests lower market correlation, but its valuation discount (trailing P/E 8.86x vs. industry ~15-20x) implies the market is pricing in significant pessimism. Competitive risks include potential market share loss in MedSurg and Dental segments, as well as technological disruption in Health Information Systems. Regulatory headwinds in healthcare and the company's status as a recent spin-off add uncertainty. The 52-week price range of $62.38 to $88.20 shows the stock has been volatile, and any negative news could trigger further downside.
Worst-Case Scenario: If revenue continues to decline at 3-5% annually, margins compress further, and free cash flow remains negative, the stock could retest its 52-week low of $62.38, representing a 20.3% decline from the current price of $78.27. In a severe downturn, the stock could fall to $55 (based on historical P/E trough of 2.5x applied to depressed earnings), implying a 29.7% loss. The realistic downside from current levels is approximately -20% to the 52-week low, but if the company reports a loss, the stock could fall further given the lack of earnings support.
FAQ
The key risks are: 1) Revenue decline risk: revenue fell 3.71% YoY in Q4 2025, and if this accelerates, earnings could suffer. 2) Cash flow risk: trailing twelve-month free cash flow is -$10 million, meaning the company is not self-funding. 3) Leverage risk: debt-to-equity of 0.997 and quarterly interest expense of $51 million strain profitability. 4) Spin-off uncertainty: as a recent spin-off from 3M, the company lacks a long track record, and execution risks are elevated. The most severe risk is a sustained revenue decline leading to net losses, which could push the stock below its 52-week low of $62.38.
The 12-month forecast is cautiously optimistic. The base case (50% probability) sees the stock trading between $85 and $100, assuming revenue decline moderates and margins stabilize. The bull case (30% probability) targets $100-$120, driven by revenue growth and margin expansion. The bear case (20% probability) sees the stock falling to $62-$75 if revenue declines accelerate. The consensus analyst target is $118.65, implying 51.6% upside. The most likely scenario is the base case, where the stock gradually recovers as the company demonstrates stability, but investors should monitor revenue trends closely.
SOLV appears undervalued based on traditional metrics. Its trailing P/E of 8.86x is well below the healthcare industry average of 15-20x, and its forward P/E of 11.11x is also low. The P/S ratio of 1.66x is near historical lows (down from 6.9x in Q4 2025). However, this discount reflects the market's concern over declining revenue and thin margins. The valuation implies the market expects continued earnings pressure. If the company can stabilize revenue and improve margins, the stock could re-rate significantly. Compared to its own history, the current P/E is near the lower end of its range (2.5x to 92.4x), suggesting it is priced for pessimism.
SOLV appears to be a good buy for value-oriented investors with a medium-term horizon, given its deeply discounted valuation (trailing P/E of 8.86x vs. industry average 15-20x) and analyst consensus target implying 51.6% upside to $118.65. However, the stock carries significant risk from declining revenue (-3.71% YoY) and negative free cash flow. It is best suited for investors who believe the company can stabilize its top line and improve margins post-spin-off. For conservative investors, waiting for evidence of revenue stabilization or positive free cash flow may be prudent. The unanimous analyst bullishness provides some comfort, but the stock is not without risk.
SOLV is better suited for medium to long-term investment (12-24 months) given its turnaround nature. The stock has a beta of 0.716, indicating lower volatility than the market, but its recent price swings (52-week range $62.38-$88.20) show it can be volatile. Short-term traders may find opportunities in the momentum, but the fundamental story requires time to play out. The company does not pay a dividend, so income investors should look elsewhere. A minimum holding period of 12 months is recommended to allow for the post-spin-off stabilization to materialize. Long-term investors should monitor revenue growth and free cash flow as key indicators of success.
